Can’t say it’s a complete surprise, having watched the Geron burn rate over the past few years. Last year, losses exceeded $110 million. So far in 2011, about $60 million. Totally unsustainable. But to just turn away from the whole field?
Unless a partner comes to the rescue, Geron Corp. is through with stem cells and is ditching its landmark acute spinal cord injury trial, the first approved use of embryonic stem cells (eSC) in a clinical setting.
This is indeed a major blow to the notion that eSC could return function to people the way the cells seemed to in rats. Learn more.
